AstraZeneca PLC CEO Pascal Soriot tells reporters: * CEO says 55 pounds per share offer from Pfizer would likely never have happened, given U.S. tax rule changes * CEO says on track to deliver 7-8 potential NME submissions in 2015-2016 * CEO says will behave like biotech company in out-licensing products * Research and development exec says 13 phase II or phase III immuno-oncology
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. Shares of AZN fell by 0.07% or $-0.05/share to $71.06. In the past year, the shares have traded as low as $61.75 and as high as $82.68. On average, 1733530 shares of AZN exchange hands on a given day and today's volume is recorded at 3301371.
Source
